title: Targeting of calcitonin gene-related peptide action as a new strategy for migraine treatment.
abstract: Migraine is a chronic, recurrent disorder, characterized by attacks of severe pain, affecting around 1% of adult population. Many studies suggest, that trigeminovascular system plays a key role in pathogenesis of migraine and other primary headaches. Calcitonin gene-related peptide (CGRP) is an endogenous substance, which is regarded a key mediator released from trigeminovascular system after stimulation of sensory nerve endings, responsible for dilatation of peripheral vessels and sensory transmission. CGRP is and extensively studied peptide as one of the most promising targets in migraine drug research. In the article we focus on the role of CGRP in the pathophysiology of migraine and present current data on CGRP antagonists and CGRP monoclonal antibodies.
authors.affiliation: Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland.
authors.forename: Olga
authors.initials: O
authors.lastname: Kuzawińska
authors.affiliation: Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Lis
authors.affiliation: Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland; The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warsaw, Poland.
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Cessak
authors.affiliation: Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland; 2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland.
authors.forename: Dagmara
authors.initials: D
authors.lastname: Mirowska-Guzel
authors.affiliation: Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland; The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warsaw, Poland. Electronic address: ebalkowiec@wum.edu.pl.
authors.forename: Ewa
authors.initials: E
authors.lastname: Bałkowiec-Iskra
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001381:Azepines / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000627:therapeutic use; D015740:Calcitonin Gene-Related Peptide / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004151:Dipeptides / Q000627:therapeutic use*; D006576:Heterocyclic Compounds, 4 or More Rings / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008881:Migraine Disorders / Q000188:drug therapy* / Q000378:metabolism; D058990:Molecular Targeted Therapy; D010879:Piperazines; D011799:Quinazolines / Q000627:therapeutic use*; D013141:Spiro Compounds / Q000627:therapeutic use
chemical_list: C548781:2-(8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro(4.5)dec-9-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro(indene-2,3'-pyrrolo(2,3-b)pyridin)-5-yl)acetamide; D000911:Antibodies, Monoclonal; D001381:Azepines; C576963:BMS-846372; D019086:Bridged Bicyclo Compounds, Heterocyclic; D004151:Dipeptides; D006576:Heterocyclic Compounds, 4 or More Rings; D007093:Imidazoles; D010879:Piperazines; D011799:Quinazolines; D013141:Spiro Compounds; C000604315:fremanezumab; C525458:telcagepant; D015740:Calcitonin Gene-Related Peptide; C406305:olcegepant
keywords: Calcitonin gene-related peptide; Calcitonin gene-related peptide antagonists; Migraine; Monoclonal antibodies